Treatment for Kaposi sarcoma herpesvirus: Great challenges with promising accomplishments

Virus Genes

Volumn 38, Issue 2, 2009, Pages 195-203

  Arav Boger, Ravit ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Angiogenesis inhibitors; Antivirals; Chemotherpy; Ganciclovir; Highly active antiretroviral therapy; Kaposi sarcoma herpes virus; MTOR; Primary effusion lymphoma; Rapamycin; Tyrosine kinase inhibitors

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ALITRETINOIN; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BLEOMYCIN; BORTEZOMIB; BUTYRIC ACID; CIDOFOVIR; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; FOSCARNET; FUMAGILLOL CHLOROACETYLCARBAMATE; GANCICLOVIR; IM 862; IMATINIB; INDINAVIR; PACLITAXEL; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 12; RETINOIC ACID; SORAFENIB; THALIDOMIDE; UNINDEXED DRUG; VALGANCICLOVIR; VALPROIC ACID; VINBLASTINE; VINCRISTINE; ZIDOVUDINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BONE MARROW SUPPRESSION; CHEILITIS; CHILL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRY SKIN; FATIGUE; FEVER; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LIVER TOXICITY; MUCOSA INFLAMMATION; NEUROPATHY; NEUTROPENIA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VIRUS GENOME; VIRUS PATHOGENESIS;

ANGIOGENESIS INHIBITORS; ANTIVIRAL AGENTS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOLOGIC FACTORS; SARCOMA, KAPOSI;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

EID: 61849139074     PISSN: 09208569     EISSN: 1572994X     Source Type: Journal    
DOI: 10.1007/s11262-008-0325-y     Document Type: Review

References (71)

1. K Antman Y Chang 2000 Kaposi's sarcoma N. Engl. J. Med. 342 1027 1038 10.1056/NEJM200004063421407
2. MA Eltom A Jemal SM Mbulaiteye SS Devesa RJ Biggar 2002 Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998 J. Natl. Cancer Inst. 94 1204 1210
3. G Di Lorenzo PA Konstantinopoulos L Pantanowitz R Di Trolio S De Placido BJ Dezube 2007 Management of AIDS-related Kaposi's sarcoma Lancet Oncol. 8 167 176 10.1016/S1470-2045(07)70036-0
4. DP Dittmer SE Krown 2007 Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus Curr. Opin. Oncol. 19 452 457 10.1097/CCO.0b013e3281eb8ea7
5. PJ Lambert AZ Shahrier AG Whitman OF Dyson AJ Reber JA McCubrey SM Akula 2007 Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis Expert Opin. Ther. Targets 11 589 599 10.1517/14728222.11.5.589
6. R Yarchoan JM Pluda KM Wyvill K Aleman IR Rodriguez-Chavez G Tosato AT Catanzaro SM Steinberg RF Little 2007 Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity Crit. Rev. Immunol. 27 401 414
7. SE Krown 2003 Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms Hematol. Oncol. Clin. North Am. 17 763 783 10.1016/S0889-8588(03)00042-X
8. C Casper A Wald 2007 The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma Curr. Top. Microbiol. Immunol. 312 289 307 10.1007/978-3-540-34344-8- 11
9. CM Klass MK Offermann 2005 Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma Curr. Opin. Oncol. 17 447 455 10.1097/01.cco.0000172823.01190.6c
10. BJ Dezube R Sullivan HB Koon 2006 Emerging targets and novel strategies in the treatment of AIDS-related Kaposi's sarcoma: bidirectional translational science J. Cell. Physiol. 209 659 662 10.1002/jcp.20795
11. G Sarek PM Ojala 2007 p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas Cell Cycle 6 2205 2209
12. B Brenner E Rakowsky A Katz H Gutman A Sulkes J Schacter E Fenig 1999 Tailoring treatment for classical Kaposi's sarcoma: comprehensive clinical guidelines Int. J. Oncol. 14 1097 1102
13. M Caccialanza S Marca R Piccinno G Eulisse 2008 Radiotherapy of classic and human immunodeficiency virus-related Kaposi's sarcoma: results in 1482 lesions J. Eur. Acad. Dermatol. Venereol. 22 297 302 10.1111/j.1468-3083.2007. 02405.x
14. C Simonelli M Spina R Cinelli R Talamini R Tedeschi A Gloghini E Vaccher A Carbone U Tirelli 2003 Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study J. Clin. Oncol. 21 3948 3954 10.1200/JCO.2003.06.013
15. G Gaidano D Capello AM Cilia A Gloghini T Perin S Quattrone A Migliazza CF Lo G Saglio V Ascoli A Carbone 1999 Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis Genes Chromosomes Cancer 24 16 23 10.1002/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2- F
16. DW Northfelt BJ Dezube JA Thommes BJ Miller MA Fischl A Friedman-Kien LD Kaplan MC Du RD Mamelok DH Henry 1998 Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial J. Clin. Oncol. 16 2445 2451
17. S Stewart H Jablonowski FD Goebel K Arasteh M Spittle A Rios D Aboulafia J Galleshaw BJ Dezube 1998 Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group J. Clin. Oncol. 16 683 691
18. M Lichterfeld N Qurishi C Hoffmann B Hochdorfer NH Brockmeyer K Arasteh S Mauss JK Rockstroh 2005 Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery Infection 33 140 147 10.1007/s15010-005- 4099-z
19. PS Gill A Tulpule BM Espina S Cabriales J Bresnahan M Ilaw S Louie NF Gustafson MA Brown C Orcutt B Winograd DT Scadden 1999 Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma J. Clin. Oncol. 17 1876 1883
20. L Welles MW Saville J Lietzau JM Pluda KM Wyvill I Feuerstein WD Figg R Lush J Odom WH Wilson MT Fajardo RW Humphrey E Feigal D Tuck SM Steinberg S Broder R Yarchoan 1998 Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma J. Clin. Oncol. 16 1112 1121
21. D Bundow DM Aboulafia 2004 Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma Am. J. Clin. Oncol. 27 81 84 10.1097/01.coc.0000045921.91037.C8
22. J Stebbing A Sanitt M Nelson T Powles B Gazzard M Bower 2006 A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy Lancet 367 1495 1502 10.1016/S0140-6736(06)68649-2
23. C Sgadari G Barillari E Toschi D Carlei I Bacigalupo S Baccarini C Palladino P Leone R Bugarini L Malavasi A Cafaro M Falchi D Valdembri G Rezza F Bussolino P Monini B Ensoli 2002 HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma Nat. Med. 8 225 232 10.1038/nm0302-225
24. V Esposito E Palescandolo EP Spugnini V Montesarchio A De Luca I Cardillo G Cortese A Baldi A Chirianni 2006 Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma Clin. Cancer Res. 12 2634 2639 10.1158/1078-0432.CCR-05-2188
25. V Martinez E Caumes L Gambotti H Ittah JP Morini J Deleuze I Gorin C Katlama F Bricaire N Dupin 2006 Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy Br. J. Cancer 94 1000 1006 10.1038/sj.bjc.6603056
26. DH Kedes D Ganem 1997 Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy J. Clin. Invest. 99 2082 2086 10.1172/JCI119380
27. RF Little JM Pluda KM Wyvill IR Rodriguez-Chavez G Tosato AT Catanzaro SM Steinberg R Yarchoan 2006 Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma Blood 107 4650 4657 10.1182/blood-2005-11-4455
28. C Casper WG Nichols ML Huang L Corey A Wald 2004 Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment Blood 103 1632 1634 10.1182/blood-2003-05-1721
29. DF Martin BD Kuppermann RA Wolitz AG Palestine H Li CA Robinson 1999 Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group N. Engl. J. Med. 340 1063 1070 10.1056/NEJM199904083401402
30. C Casper EM Krantz L Corey SR Kuntz J Wang S Selke S Hamilton ML Huang A Wald 2008 Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial J. Infect. Dis. 198 23 30 10.1086/588820
31. SP Perrine O Hermine T Small F Suarez R O'Reilly F Boulad J Fingeroth M Askin A Levy SJ Mentzer M Di Nicola AM Gianni C Klein S Horwitz DV Faller 2007 A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood 109 2571 2578 10.1182/blood-2006-01-024703
32. CM Klass LT Krug VP Pozharskaya MK Offermann 2005 The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production Blood 105 4028 4034 10.1182/blood-2004-09-3569
33. M.J. Lechowicz, J. Lee, D. Dittmer, S. Krown, J. Said, R.F. Ambinder, A pilot trial of valproic acid in patients with Kaposi's sarcoma: a Multi-Center Trial of the AIDS Malignancy Consortium. American Society of Hematology, 12-9-2007. Ref Type: Conference Proceeding
34. T Maurer M Ponte K Leslie 2007 HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load N. Engl. J. Med. 357 1352 1353 10.1056/NEJMc070508
35. SE Krown JY Lee DP Dittmer 2008 More on HIV-associated Kaposi's sarcoma N. Engl. J. Med. 358 535 536 10.1056/NEJMc072994
36. F Curreli AE Friedman-Kien O Flore 2005 Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes J. Clin. Invest. 115 642 652
37. Q Jia R Sun 2003 Inhibition of gammaherpesvirus replication by RNA interference J. Virol. 77 3301 3306 10.1128/JVI.77.5.3301-3306.2003
38. A Godfrey J Anderson A Papanastasiou Y Takeuchi C Boshoff 2005 Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA Blood 105 2510 2518 10.1182/blood-2004-08-3052
39. G Stallone A Schena B Infante S Di Paolo A Loverre G Maggio E Ranieri L Gesualdo FP Schena G Grandaliano 2005 Sirolimus for Kaposi's sarcoma in renal-transplant recipients N. Engl. J. Med. 352 1317 1323 10.1056/NEJMoa042831
40. A Sodhi R Chaisuparat J Hu AK Ramsdell BD Manning EA Sausville ET Sawai A Molinolo JS Gutkind S Montaner 2006 The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor Cancer Cell 10 133 143 10.1016/j.ccr.2006.05.026
41. SH Sin D Roy L Wang MR Staudt FD Fakhari DD Patel D Henry WJ Harrington Jr BA Damania DP Dittmer 2007 Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling Blood 109 2165 2173 10.1182/blood-2006-06-028092
42. C Lebbe S Euvrard B Barrou C Pouteil-Noble JL Garnier D Glotz C Legendre C Frances 2006 Sirolimus conversion for patients with posttransplant Kaposi's sarcoma Am. J. Transplant. 6 2164 2168 10.1111/j.1600-6143.2006.01412.x
43. PA Konstantinopoulos RJ Sullivan MV Karamouzis BJ Dezube 2007 Investigational agents for treatment of AIDS-related Kaposi's sarcoma Expert Opin. Investig. Drugs 16 495 504 10.1517/13543784.16.4.495
44. M Sturzl WK Roth NH Brockmeyer C Zietz B Speiser PH Hofschneider 1992 Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance Proc. Natl Acad. Sci. USA 89 7046 7050 10.1073/pnas.89.15.7046
45. HB Koon GJ Bubley L Pantanowitz D Masiello B Smith K Crosby J Proper W Weeden TE Miller P Chatis MJ Egorin SR Tahan BJ Dezube 2005 Imatinib-induced regression of AIDS-related Kaposi's sarcoma J. Clin. Oncol. 23 982 989 10.1200/JCO.2005.06.079
46. C Sgadari AL Angiolillo G Tosato 1996 Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10 Blood 87 3877 3882
47. M Clerici DR Lucey JA Berzofsky LA Pinto TA Wynn SP Blatt MJ Dolan CW Hendrix SF Wolf GM Shearer 1993 Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro Science 262 1721 1724 10.1126/science. 7903123
48. FX Real HF Oettgen SE Krown 1986 Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon J. Clin. Oncol. 4 544 551
49. SE Krown JW Gold D Niedzwiecki D Bundow N Flomenberg B Gansbacher BJ Brew 1990 Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS) Ann. Intern. Med. 112 812 821
50. S Vadhan-Raj G Wong C Gnecco S Cunningham-Rundles M Krim FX Real HF Oettgen SE Krown 1986 Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome Cancer Res. 46 417 425
51. FA Shepherd R Beaulieu K Gelmon CA Thuot C Sawka S Read J Singer 1998 Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study J. Clin. Oncol. 16 1736 1742
52. SE Krown JY Lee L Lin MA Fischl R Ambinder JH Von Roenn 2006 Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial J. Acquir. Immune Defic. Syndr. 41 149 153 10.1097/01.qai. 0000194237.15831.23
53. M Opravil B Hirschel HC Bucher R Luthy 1999 A randomized trial of interferon-alpha2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi's sarcoma. Swiss HIV Cohort Study Int. J. STD AIDS 10 369 375 10.1258/0956462991914285
54. A Kreuter H Rasokat M Klouche S Esser A Bader T Gambichler P Altmeyer NH Brockmeyer 2005 Liposomal pegylated doxorubicin versus low-dose recombinant interferon alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers Cancer Invest. 23 653 659 10.1080/07357900500358259
55. RF Little KM Wyvill JM Pluda L Welles V Marshall WD Figg FM Newcomb G Tosato E Feigal SM Steinberg D Whitby JJ Goedert R Yarchoan 2000 Activity of thalidomide in AIDS-related Kaposi's sarcoma J. Clin. Oncol. 18 2593 2602
56. WX Guo PS Gill T Antakly 1995 Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation Cancer Res. 55 823 829
57. S Nagpal J Cai T Zheng S Patel R Masood GY Lin S Friant A Johnson DL Smith RA Chandraratna PS Gill 1997 Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma Mol. Cell. Biol. 17 4159 4168
58. PS Gill BM Espina T Moudgil S Kidane JA Esplin A Tulpule AM Levine 1994 All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study Leukemia 8 Suppl 3 S26 S32
59. P Saiag M Pavlovic T Clerici V Feauveau JC Nicolas D Emile C Chastang 1998 Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. Kaposi's Sarcoma ANRS Study Group. Agence Nationale de Recherches sur le SIDA AIDS 12 2169 2176 10.1097/00002030-199816000-00012
60. BJ Dezube JH Von Roenn J Holden-Wiltse TW Cheung SC Remick TP Cooley J Moore JP Sommadossi SL Shriver CW Suckow PS Gill 1998 Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team J. Clin. Oncol. 16 1444 1449
61. A Noy DT Scadden J Lee BJ Dezube D Aboulafia A Tulpule S Walmsley P Gill 2005 Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team J. Clin. Oncol. 23 990 998 10.1200/JCO.2005.11.043
62. AM Levine A Tulpule DI Quinn G Gorospe III DL Smith L Hornor WD Boswell BM Espina SG Groshen R Masood PS Gill 2006 Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy J. Clin. Oncol. 24 1712 1719 10.1200/JCO.2005.03.4801
63. SA Keller EJ Schattner E Cesarman 2000 Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells Blood 96 2537 2542
64. R Abou-Merhi R Khoriaty D Arnoult H El Hajj H Dbouk S Munier ME El Sabban O Hermine A Gessain H de The R Mahieux A Bazarbachi 2007 PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells Leukemia 21 1792 1801 10.1038/sj.leu.2404797
65. D Blankaert T Simonart JP Van Vooren D Parent C Liesnard CM Farber T Marique J Werenne 1998 Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18 203 209
66. BJ Dezube SE Krown JY Lee KS Bauer DM Aboulafia 2006 Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study J. Clin. Oncol. 24 1389 1394 10.1200/JCO.2005.04.2614
67. R Dell'Eva U Pfeffer R Vene L Anfosso A Forlani A Albini T Efferth 2004 Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate Biochem. Pharmacol. 68 2359 2366 10.1016/j.bcp.2004.08.021
68. C Bais B Santomasso O Coso L Arvanitakis EG Raaka JS Gutkind AS Asch E Cesarman MC Gershengorn EA Mesri 1998 G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator Nature 391 86 89 10.1038/34193
69. S Montaner A Sodhi AK Ramsdell D Martin J Hu ET Sawai JS Gutkind 2006 The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma Cancer Res. 66 168 174 10.1158/0008-5472.CAN-05-1026
70. MJ Martin T Tanos AB Garcia D Martin JS Gutkind OA Coso MJ Marinissen 2007 The Galpha12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus G protein-coupled receptor to heme oxygenase-1 expression and tumorigenesis J. Biol. Chem. 282 34510 34524 10.1074/jbc.M703043200
71. DX Fu Y Tanhehco J Chen CA Foss JJ Fox JM Chong RF Hobbs M Fukayama G Sgouros J Kowalski MG Pomper RF Ambinder 2008 Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors Nat. Med. 14 1118 1122 10.1038/nm.1864